Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application No. 19/253,088, titled ...
Investor's Business Daily on MSN
Travere, IBD stock of the day, is on path to $3 billion and in a buy zone
Travere Therapeutics is Thursday's IBD Stock Of The Day. Shares are lingering around a buy zone after gapping up on an FDA ...
Investor's Business Daily on MSN
Dow Jones leader Amazon, AI stock Quanta, Monster Beverage in or near buy zones
Dow Jones leader Amazon stock and AI stock Quanta Services are in or near buy zones in the ongoing stock market rally.
For the first quarter of 2026, the Nomura Small Cap Core Fund Institutional shares underperformed the Russell 2000 Index, ...
What are the most attractive biotech stocks right now for investors? Seeking Alpha analysts offer their picks. Read more here.
Expense ratios, yield, and sector breadth set these healthcare ETFs apart—see how their risk profiles and portfolio ...
The FDA has delayed a decision on the approval of AstraZeneca’s camizestrant, deferring its ruling to review analyses filed ...
Years of legal battles have culminated in a decisive judgment against a well-known Toronto plastic surgeon, Dr. Martin Jugenburg. The ruling follows a comprehensive five-week common issues trial that ...
Vera Therapeutics Inc. research and ratings by Barron's. View VERA revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results